(c) 2024 PillSync.com

glipizide 2.5 mg extended release

1 INDICATIONS AND USAGE Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Glipizide extended-release tablets is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. 1.1 Limitations of Use Glipizide extended-release tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

american health packaging


2 years ago ROUND WHITE A glipizide 2.5 mg extended release

ROUND WHITE A

16 HOW SUPPLIED/STORAGE AND HANDLING

GLIPIZIDE Extended-Release Tablets, 2.5 mg are white to off-white, round, biconvex film-coated tablets imprinted with ‘A’ on one side with black ink. Unit dose packages of 30 (3 x 10) NDC 60687-480-21 Recommended Storage: The tablets should be protected from moisture and humidity. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken.


More pills like ROUND A

Related Pills

glipizide 10 mg extended release

american health packaging

dronabinol capsule

camber pharmaceuticals inc

dronabinol capsule

camber pharmaceuticals inc

dronabinol capsule

camber pharmaceuticals inc

nizoral ketoconazole 200 mg tablet

janssen pharmaceutical products

Acetaminophen 650 mg Hydrocodone 10 mg

watson laboratories, inc.












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site